The Life Sciences team advised Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on the R&D funding component of its previously announced $2 billion strategic financing collaboration with Blackstone (NYSE: BX) to accelerate the advancement of RNAi therapeutics.
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, infectious, and central nervous system (CNS)/ocular diseases.
Under the terms of the agreement, Alnylam will receive up to $150 million from Blackstone Life Sciences for the development of Alnylam’s cardiometabolic disease programs vutrisiran and ALN-AGT. The investment includes up to $70 million to support the ongoing HELIOS-B Phase 3 study of vutrisiran in ATTR amyloidosis patients with cardiomyopathy, and up to $80 million to support Phase 2 and Phase 3 development of ALN-AGT, in development for the treatment of hypertension.
The Goodwin team was led by Shane Albright and Kingsley Taft and included Matt Ambros, Chris Steinroeder, Dan Karelitz and Nicole Spiteri.
For more details, read the press release and articles in Endpoints, The Pharma Letter, and Boston Business Journal.